. Before resistance developed, monoclonal antibodies were highly effective in preventing severe COVID-19 - IOPAC Press "Enter" to skip to content

WHO lists additional mpox diagnostic tests for emergency use
- All WHO news
As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox...
WHO and partners activate Global Health Emergency Corps for the first time in response to mpox outbreak
- All WHO news
In October 2024, WHO and partners, in collaboration with Member States, activated the Global Health Emergency Corps (GHEC) for the...
Intense bombardments, mass displacements and lack of access in northern Gaza force the postponement of polio vaccination campaign
- All WHO news
Due to the escalating violence, intense bombardment, mass displacement orders, and lack of assured humanitarian pauses across most of northern...

The right to health
- WHO Director-General speeches
Excellencies, ladies and gentlemen, Good afternoon, and thank you for having me. It’s a real honour to be with you...
Closing address at High-Level Action Day, First WHO Global Conference on Air Pollution and Health
- WHO Director-General speeches
Every human being is entitled to breathe clean air. It’s a human right. We are honoured to have the Human...
Opening address at the First WHO Global Conference on Air Pollution and Health
- WHO Director-General speeches
Excellency, second Lady Hajia Samira Bawumia of Ghana, my colleague colleague Dr Taalas, Secretary General of WMO and my sister...

Before resistance developed, monoclonal antibodies were highly effective in preventing severe COVID-19

By iopac on April 26, 2023

The drugs were highly safe and effective at reducing the severity of COVID-19 infections before the latest variants, especially among unvaccinated people.

Published in COVID-19

iopac

More from COVID-19More posts in COVID-19 »